Canada Life’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Canada Life’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-900	Closed	-$6K	–	2785
2018 Q3	$6K	Hold	900	–	–	﹤0.01%	2565
2018 Q2	$7K	Hold	900	–	–	﹤0.01%	2568
2018 Q1	$20K	Hold	900	–	–	﹤0.01%	2506
2017 Q4	$11K	Hold	900	–	–	﹤0.01%	2519
2017 Q3	$14K	Hold	900	–	–	﹤0.01%	2515
2017 Q2	$13K	Buy	+900	New	+$19.3K	﹤0.01%	2526

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Canada Life's JNCE Position: Q4 2018 in Review

Canada Life sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2018, closing a stake of 900 shares — an estimated $6K sold.

Canada Life first reported a position in JNCE in Q2 2017 and held it in 6 quarters. The position peaked at $20K in Q1 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q4 2018.

Canada Life reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Canada Life sold 900 Jounce Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $6K.
Canada Life first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
Canada Life's Jounce Therapeutics, Inc. Common Stock position peaked at $20K in Q1 2018.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Canada Life's 13F filing for Q4 2018, filed 12 Feb 2019.